New drug cocktail tested for fighting advanced kidney cancer

NCT ID NCT04626479

Ongoing Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

Summary

This study is testing experimental combinations of immune and targeted drugs for people with advanced kidney cancer that has spread. The research aims to find safe and effective treatment options for 400 participants who haven't received prior treatment for their advanced cancer. The trial has two parts: first checking safety, then measuring how well the treatments work against the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Asan Medical Center ( Site 1800)

Songpagu, Seoul, 05505, South Korea
Auckland City Hospital ( Site 1700)

Auckland, 1023, New Zealand
Austin Health ( Site 1600)

Heidelberg, Victoria, 3084, Australia
Barts Health NHS Trust ( Site 1401)

London, London, City of, EC1A 7BE, United Kingdom
Bradfordhill-Clinical Area ( Site 2101)

Santiago, Region M. de Santiago, 8420383, Chile
CIDO SpA-Oncology ( Site 2106)

Temuco, Región de la Araucanía, 4810148, Chile
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2201)

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 1900)

Bogotá, Bogota D.C., 111321, Colombia
Duke Cancer Institute ( Site 1015)

Durham, North Carolina, 27710, United States
Erasmus Medisch Centrum ( Site 2401)

Rotterdam, South Holland, 3015 GD, Netherlands
FALP-UIDO ( Site 2100)

Santiago, Region M. de Santiago, 7500921, Chile
Fundación Valle del Lili ( Site 1901)

Cali, Valle del Cauca Department, 760032, Colombia
Gustave Roussy ( Site 1202)

Villejuif, Val-de-Marne, 94800, France
Hadassah Medical Center-Oncology ( Site 1504)

Jerusalem, 9112001, Israel
Henry Ford Health System ( Site 1014)

Detroit, Michigan, 48202, United States
Hospital Universitari Vall d Hebron ( Site 1300)

Barcelona, Catalonia, 08035, Spain
Hospital Universitario Ramon y Cajal ( Site 1301)

Madrid, 28034, Spain
Institut Claudius Regaud ( Site 1200)

Toulouse, Haute-Garonne, 31059, France
Institut De Cancerologie De Lorraine ( Site 1204)

Vandœuvre-lès-Nancy, Ain, 54519, France
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1203)

Strasbourg, Alsace, 67200, France
James Lind Centro de Investigación del Cáncer ( Site 2108)

Temuco, Región de la Araucanía, 4800827, Chile
Jewish General Hospital ( Site 1100)

Montreal, Quebec, H3T 1E2, Canada
Laura and Isaac Perlmutter Cancer Center ( Site 1016)

New York, New York, 10016, United States
Leicester Royal Infirmary ( Site 1408)

Leicester, Leicestershire, LE1 5WW, United Kingdom
Memorial Sloan Kettering Cancer Center ( Site 1002)

New York, New York, 10065, United States
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 2200

Warsaw, Masovian Voivodeship, 02-781, Poland
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 2402)

Amsterdam, North Holland, 1066CX, Netherlands
ONCOCENTRO APYS-ACEREY ( Site 2103)

Viña del Mar, Región de Valparaíso, 2520598, Chile
Oncomédica S.A.S ( Site 1904)

Montería, Departamento de Córdoba, 230002, Colombia
Oncovida ( Site 2107)

Santiago, Region M. de Santiago, 7510032, Chile
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 2301)

Budapest, Pest County, 1122, Hungary
Princess Margaret Cancer Centre ( Site 1101)

Toronto, Ontario, M5G 1Z5, Canada
Rabin Medical Center ( Site 1502)

Petah Tikva, 4941492, Israel
Rambam MC ( Site 1500)

Haifa, 3525408, Israel
Royal Brisbane and Women s Hospital ( Site 1603)

Herston, Queensland, 4029, Australia
Royal Preston Hospital ( Site 1406)

Preston, Lancashire, PR2 9HT, United Kingdom
Samsung Medical Center ( Site 1801)

Seoul, 06351, South Korea
Severance Hospital ( Site 1802)

Seoul, 03722, South Korea
Sheba Medical Center - Oncology Division ( Site 1501)

Ramat Gan, 52621, Israel
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1905)

Valledupar, Cesar Department, 200001, Colombia
Sourasky Medical Center ( Site 1503)

Tel Aviv, 6423906, Israel
Southampton General Hospital ( Site 1403)

Southampton, England, SO16 6YD, United Kingdom
St George Hospital ( Site 1602)

Kogarah, New South Wales, 2217, Australia
The Beatson West of Scotland Cancer Centre ( Site 1405)

Glasgow, Glasgow City, G12 0YN, United Kingdom
The Christie NHS Foundation Trust ( Site 1400)

Manchester, M20 4BX, United Kingdom
UPMC Cancer Center/Hillman Cancer Center ( Site 1017)

Pittsburgh, Pennsylvania, 15232, United States
UTSW Medical Center ( Site 1003)

Dallas, Texas, 75390, United States
University of California at San Francisco ( Site 1008)

San Francisco, California, 94158, United States
University of Chicago ( Site 1013)

Chicago, Illinois, 60637, United States
University of Iowa ( Site 1012)

Iowa City, Iowa, 52242, United States
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 2202)

Gdansk, Pomeranian Voivodeship, 80-952, Poland
Velindre Cancer Centre Hospital ( Site 1407)

Cardiff, Wales, CF14 2TL, United Kingdom
Western General Hospital ( Site 1402)

Edinburgh, Midlothian, EH4 2XU, United Kingdom
Western Sydney Local Health District ( Site 1601)

Blacktown, New South Wales, 2148, Australia
Yale-New Haven Hospital-Yale Cancer Center ( Site 1011)

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

CARCINOMA, RENAL CELL